Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.

Carlsen AL, Joergensen MT, Knudsen S, de Muckadell OB, Heegaard NH.

Pancreas. 2013 Oct;42(7):1107-13. doi: 10.1097/MPA.0b013e318296bb34.

PMID:
24048453
2.

MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.

Xue Y, Abou Tayoun AN, Abo KM, Pipas JM, Gordon SR, Gardner TB, Barth RJ Jr, Suriawinata AA, Tsongalis GJ.

Cancer Genet. 2013 Jun;206(6):217-21. doi: 10.1016/j.cancergen.2013.05.020. Epub 2013 Aug 9.

PMID:
23933230
3.

Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma.

Zhao C, Zhang J, Zhang S, Yu D, Chen Y, Liu Q, Shi M, Ni C, Zhu M.

Oncol Rep. 2013 Jul;30(1):276-84. doi: 10.3892/or.2013.2420. Epub 2013 Apr 23.

PMID:
23612862
4.

Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.

Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M, Yamaguchi K, Hashimoto H.

Mod Pathol. 2012 Jan;25(1):112-21. doi: 10.1038/modpathol.2011.142. Epub 2011 Oct 7.

5.

Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.

Zhang J, Zhao CY, Zhang SH, Yu DH, Chen Y, Liu QH, Shi M, Ni CR, Zhu MH.

Oncol Rep. 2014 Mar;31(3):1157-64. doi: 10.3892/or.2013.2960. Epub 2013 Dec 31.

PMID:
24398877
6.

A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.

Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M.

Cancer Lett. 2017 May 1;393:86-93. doi: 10.1016/j.canlet.2017.02.019. Epub 2017 Feb 20.

7.

Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.

Munding JB, Adai AT, Maghnouj A, Urbanik A, Zöllner H, Liffers ST, Chromik AM, Uhl W, Szafranska-Schwarzbach AE, Tannapfel A, Hahn SA.

Int J Cancer. 2012 Jul 15;131(2):E86-95. doi: 10.1002/ijc.26466. Epub 2011 Nov 19.

8.

Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.

Yabushita S, Fukamachi K, Tanaka H, Sumida K, Deguchi Y, Sukata T, Kawamura S, Uwagawa S, Suzui M, Tsuda H.

Pancreas. 2012 Oct;41(7):1013-8. doi: 10.1097/MPA.0b013e31824ac3a5.

PMID:
22513294
9.

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.

Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H.

J Hematol Oncol. 2012 Apr 4;5:15. doi: 10.1186/1756-8722-5-15.

10.

miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.

Alemar B, Izetti P, Gregório C, Macedo GS, Castro MA, Osvaldt AB, Matte U, Ashton-Prolla P.

Pancreas. 2016 Jan;45(1):84-92. doi: 10.1097/MPA.0000000000000383.

PMID:
26262588
11.

Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.

Distler M, Pilarsky E, Kersting S, Grützmann R.

Int J Surg. 2013;11(10):1067-72. doi: 10.1016/j.ijsu.2013.10.005. Epub 2013 Oct 23.

12.

A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.

Cote GA, Gore AJ, McElyea SD, Heathers LE, Xu H, Sherman S, Korc M.

Am J Gastroenterol. 2014 Dec;109(12):1942-52. doi: 10.1038/ajg.2014.331. Epub 2014 Oct 28.

13.

High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer.

Giovannetti E, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE, Gallá V, Sudo H, Falcone A, Campani D, Boggi U, Peters GJ.

PLoS One. 2012;7(11):e49145. doi: 10.1371/journal.pone.0049145. Epub 2012 Nov 14.

14.

MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.

Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA.

Clin Cancer Res. 2012 Jan 15;18(2):534-45. doi: 10.1158/1078-0432.CCR-11-0679. Epub 2011 Nov 23.

15.

MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma.

Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA.

Oncogene. 2007 Jun 28;26(30):4442-52. Epub 2007 Jan 22.

PMID:
17237814
16.

Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.

Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J.

Ann Surg Oncol. 2009 Aug;16(8):2339-50. doi: 10.1245/s10434-009-0531-4. Epub 2009 May 28.

PMID:
19475450
17.

Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance.

Ma MZ, Kong X, Weng MZ, Cheng K, Gong W, Quan ZW, Peng CH.

J Exp Clin Cancer Res. 2013 Sep 28;32:71. doi: 10.1186/1756-9966-32-71. Review.

18.

MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions.

du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, Tsongalis GJ, Suriawinata AA, Carrère N, Buscail L, Cordelier P.

Clin Chem. 2010 Apr;56(4):603-12. doi: 10.1373/clinchem.2009.137364. Epub 2010 Jan 21.

19.

Metabolomic and transcriptomic profiling of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.

Yabushita S, Fukamachi K, Tanaka H, Fukuda T, Sumida K, Deguchi Y, Mikata K, Nishioka K, Kawamura S, Uwagawa S, Suzui M, Alexander DB, Tsuda H.

Carcinogenesis. 2013 Jun;34(6):1251-9. doi: 10.1093/carcin/bgt053. Epub 2013 Feb 7.

PMID:
23393225
20.

Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.

Wang X, Li Y, Tian H, Qi J, Li M, Fu C, Wu F, Wang Y, Cheng D, Zhao W, Zhang C, Wang T, Rao J, Zhang W.

BMC Cancer. 2014 Aug 8;14:578. doi: 10.1186/1471-2407-14-578.

Supplemental Content

Support Center